Home
COEP
COEP News

Latest Coeptis Therapeutics Holdings Inc. (COEP) News on August 29, 2025

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

GlobeNewswire

3 months ago

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

MT Newswires

4 months ago

Coeptis Therapeutics Subsidiary to Merge With Dogecoin Mining Company

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

GlobeNewswire

6 months ago

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

GlobeNewswire

6 months ago

COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

GlobeNewswire

6 months ago

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

Coeptis Therapeutics (COEP): Launching AI-Focused Venture Arm to Fuel Innovation

Insider Monkey

6 months ago

Coeptis Therapeutics (COEP): Launching AI-Focused Venture Arm to Fuel Innovation

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

GlobeNewswire

7 months ago

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

Coeptis Therapeutics Holdings, Inc. (COEP) Raises $10M to Advance AI-Driven Cell Therapy Innovations

Insider Monkey

7 months ago

Coeptis Therapeutics Holdings, Inc. (COEP) Raises $10M to Advance AI-Driven Cell Therapy Innovations

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

PR Newswire

7 months ago

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Coeptis Therapeutics Holdings, Inc. (COEP): Pioneering AI-Powered Marketing for Healthcare Innovation

Insider Monkey

7 months ago

Coeptis Therapeutics Holdings, Inc. (COEP): Pioneering AI-Powered Marketing for Healthcare Innovation

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

PR Newswire

7 months ago

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

PR Newswire

7 months ago

Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

PR Newswire

7 months ago

Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

PR Newswire

8 months ago

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

Why Is Coeptis Therapeutics Stock Falling On Friday?

Benzinga

8 months ago

Why Is Coeptis Therapeutics Stock Falling On Friday?

MT Newswires

8 months ago

Coeptis Therapeutics to Implement 1-for-20 Reverse Stock Split

Coeptis Therapeutics Announces Reverse Stock Split

PR Newswire

8 months ago

Coeptis Therapeutics Announces Reverse Stock Split

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

PR Newswire

8 months ago

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

PR Newswire

9 months ago

Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

PR Newswire

9 months ago

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

PR Newswire

10 months ago

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

PR Newswire

10 months ago

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

PR Newswire

10 months ago

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

MT Newswires

a year ago

Coeptis Therapeutics Receives Nasdaq Listing Extension

Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

PR Newswire

a year ago

Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders

PR Newswire

a year ago

Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

PR Newswire

a year ago

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

MT Newswires

a year ago

--Ladenburg Downgrades Coeptis Therapeutics to Neutral From Buy

Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting

PR Newswire

a year ago

Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

PR Newswire

a year ago

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

PR Newswire

a year ago

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

PR Newswire

a year ago

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/21/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/20/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/19/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/18/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/15/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/14/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/13/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/12/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/11/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/08/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/07/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/06/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/05/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/04/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 03/01/2024

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 02/29/2024

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 02/28/2024

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 02/27/2024

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

PR Newswire

2 years ago

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 02/26/2024

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 02/23/2024

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 02/22/2024

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 02/21/2024

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 02/20/2024

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 02/16/2024

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

PR Newswire

2 years ago

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

All You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buy

Zacks

2 years ago

All You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buy

Business Wire

2 years ago

Electromed, Inc. Schedules its Second Quarter Fiscal 2024 Financial Results Conference Call for February 13, 2024 at 5:00 p.m. ET

Business Wire

2 years ago

Electromed, Inc. Announces Partnership to Expand SmartVest Access to Veterans, Federal Employees, and Native American Communities

SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market

GlobeNewswire

2 years ago

SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market

Caravelle, a model of Sino-French co-operation, was praised by many media at the Davos Summit 2024

PR Newswire

2 years ago

Caravelle, a model of Sino-French co-operation, was praised by many media at the Davos Summit 2024

Business Wire

2 years ago

Wag! To Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024

Business Wire

2 years ago

Electromed, Inc. to Participate in the Virtual 2024 Lytham Partners Investor Select Conference

After losing 41% in the past year, Neuronetics, Inc. (NASDAQ:STIM) institutional owners must be relieved by the recent gain

Simply Wall St.

2 years ago

After losing 41% in the past year, Neuronetics, Inc. (NASDAQ:STIM) institutional owners must be relieved by the recent gain

Alpha Modus Retains Christopher E. Hanba for the Purpose of Intellectual Property Rights Litigation

GlobeNewswire

2 years ago

Alpha Modus Retains Christopher E. Hanba for the Purpose of Intellectual Property Rights Litigation

Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

GlobeNewswire

2 years ago

Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround

Zacks

2 years ago

Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround

Wag! Pet Care Solutions Now Available through Bright Horizons

Business Wire

2 years ago

Wag! Pet Care Solutions Now Available through Bright Horizons

Seth Klarman's Exit from Atara Biotherapeutics Inc

GuruFocus.com

2 years ago

Seth Klarman's Exit from Atara Biotherapeutics Inc

Carbon Revolution plc Wheel Production More Than Tripled in Q4 CY2023 from Previous Year Quarter

GlobeNewswire

2 years ago

Carbon Revolution plc Wheel Production More Than Tripled in Q4 CY2023 from Previous Year Quarter

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

PR Newswire

2 years ago

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program

PR Newswire

2 years ago

INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program

Electrovaya Announces Date for Q4 FY-2023 and FY-2023 Financial Results and Conference Call

ACCESSWIRE

2 years ago

Electrovaya Announces Date for Q4 FY-2023 and FY-2023 Financial Results and Conference Call

United Security Bancshares's Dividend Analysis

GuruFocus.com

2 years ago

United Security Bancshares's Dividend Analysis

Canadian Investment Regulatory Organization Trade Resumption - DGHI

CNW Group

2 years ago

Canadian Investment Regulatory Organization Trade Resumption - DGHI

Beyond Air Independent Director Acquires 102% More Stock

Simply Wall St.

2 years ago

Beyond Air Independent Director Acquires 102% More Stock

Reuters

2 years ago

AlloVir scraps late-stage studies testing antiviral cell therapy

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

GlobeNewswire

2 years ago

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

BiggerPockets Podcast Network Moves to Cumulus

GlobeNewswire

2 years ago

BiggerPockets Podcast Network Moves to Cumulus

ProMIS Neurosciences Announces Publication on Novel Target for ALS

GlobeNewswire

2 years ago

ProMIS Neurosciences Announces Publication on Novel Target for ALS

ACHV: Not So Fast…

Zacks Small Cap Research

2 years ago

ACHV: Not So Fast…

We Think Shareholders May Want To Consider A Review Of Allot Ltd.'s (NASDAQ:ALLT) CEO Compensation Package

Simply Wall St.

2 years ago

We Think Shareholders May Want To Consider A Review Of Allot Ltd.'s (NASDAQ:ALLT) CEO Compensation Package

Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now

GlobeNewswire

2 years ago

Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now

GlobeNewswire

2 years ago

Digihost Provides November 2023 Production Update

Coeptis Therapeutics to Present at the Emerging Growth Conference

PR Newswire

2 years ago

Coeptis Therapeutics to Present at the Emerging Growth Conference

Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth

InvestorPlace

2 years ago

Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth

Deswell Industries, Inc. (NASDAQ:DSWL) Pays A US$0.10 Dividend In Just Three Days

Simply Wall St.

2 years ago

Deswell Industries, Inc. (NASDAQ:DSWL) Pays A US$0.10 Dividend In Just Three Days

Business Wire

2 years ago

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

Investors in Eltek (NASDAQ:ELTK) have seen splendid returns of 281% over the past five years

Simply Wall St.

2 years ago

Investors in Eltek (NASDAQ:ELTK) have seen splendid returns of 281% over the past five years

Lightbridge CEO Seth Grae Interviewed on Scripps News TV

GlobeNewswire

2 years ago

Lightbridge CEO Seth Grae Interviewed on Scripps News TV

Business Wire

2 years ago

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

GlobeNewswire

2 years ago

Digihost Reports Positive Year Over Year Revenue Growth and 49% Increase in EBITDA* for Q3 2023

Interlink Electronics Reports Third Quarter 2023 Results

PR Newswire

2 years ago

Interlink Electronics Reports Third Quarter 2023 Results

GoHealth Inc (GOCO) Reports Mixed Third Quarter 2023 Results

GuruFocus.com

2 years ago

GoHealth Inc (GOCO) Reports Mixed Third Quarter 2023 Results

Business Wire

2 years ago

Electromed, Inc. Announces Fiscal 2024 First Quarter Financial Results

Cepton’s Lidar Technology Deployed by The Indoor Lab to Revolutionize Operations at Tampa International Airport

Business Wire

2 years ago

Cepton’s Lidar Technology Deployed by The Indoor Lab to Revolutionize Operations at Tampa International Airport

Don't Race Out To Buy Territorial Bancorp Inc. (NASDAQ:TBNK) Just Because It's Going Ex-Dividend

Simply Wall St.

2 years ago

Don't Race Out To Buy Territorial Bancorp Inc. (NASDAQ:TBNK) Just Because It's Going Ex-Dividend

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

PR Newswire

2 years ago

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

Share on Social Networks: